Opioid Abuse Deterrence, Research, and Recovery Act of 2017

Summary

Opioid Abuse Deterrence, Research, and Recovery Act of 2017 This bill amends the Controlled Substances Act to prohibit the Drug Enforcement Administration from registering, or renewing the registration of, a practitioner who is licensed to prescribe opioids in schedule II or III unless the practitioner agrees to limit an opioid prescription for the initial treatment of acute pain to the lesser of a seven-day supply (no refill) or an opioid prescription limit established under state law. Certain opioid prescriptions are not subject to the limit (e.g., an opioid that is approved and prescribed for the treatment of an opioid use disorder). The Food and Drug Administration (FDA) must continue to work with stakeholders to promote the development of abuse-deterrent opioid formulations. The bill requires: (1) the Government Accountability Office to study and report on health care policy changes that may have contributed to the increase in opioid overdoses and deaths, and (2) the FDA to study the feasibility of replacing opioid prescribing limits established by this bill with evidence-based clinical guidelines for opioid prescribing.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 29 November 2017

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

2. 29 November 2017

   Introduced

   Introduced in House

   Source: IntroReferral

3. 29 November 2017

   Introduced

   Introduced in House

   Source: IntroReferral

4. 1 December 2017

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

5. 9 January 2018

   Referred

   Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 29 November 2017 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 29 November 2017

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 29 November 2017

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 29 November 2017

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Meadows, Mark [R-NC-11] · R · Sponsor
• James Renacci · R · Sponsor
• Sen. Budd, Ted [R-NC] · R · Cosponsor
• · hsju00 · Standing
• · hsif00 · Standing

Related records

• related to → Opioid Addiction Prevention Act of 2017
• related to → Opioid Addiction Prevention Act of 2017
• related to ← To require a study and report on policy and regulatory changes that may have contributed to the opioid epidemic.